"Cervical Cancer Diagnostic Test Market to Exhibit Profitable Growth during the Forecast Period"

The global cervical cancer diagnostic test market market is growing significantly, was valued at US$ 8,779.2 Mn in 2017 and expected to attain US$ XX Mn by 2026. Worldwide growing prevalence of cervical cancer along with growing female population aged between 25 to 60 years are the major factors driving the overall growth of the global cervical cancer diagnostic test market. In addition, new technological progresses in HPV test and Pap (Papanicolaou) test is generating major revenue from the developed markets. Also, favorable private and public initiatives in the medical sector across various developing countries, product expansion, and increasing lab tests with higher acceptance of instruments and kits will further assist in the overall cervical cancer diagnostic test market growth.

The Pap test segment is leading the worldwide market in 2017. Pap (Papanicolaou) test is a screening test, and is generally the first step in determining cervical health. Enhanced Pap test screenings have made it simpler for doctors and specialists to discover cancerous cells. Digital screening, regularly called FocalPoint or AutoPap, utilizes a computer to filter the sample for abnormal cells. The improvement in computer-guided cancer tests to minimize the errors along with improved precision is expected to drive the growth of the market. Pap tests give continuous comprehension of current cell development, and demonstrate whether strange cell development is probably going to wind up malignant in the close term if left untreated. Furthermore, the HPV (Human papillomavirus) test is utilized to recognize disease with high hazard HPV, the infection that causes cervical disease. Over 90% of cervical malignancies happen because of HPV infection and they are analyzed through Pap smear screening and HPV test. The most well-known types of cervical cell tumor incorporate Adenocarcinoma and Squamous Cell Malignancy.

Various screening tests for females with symptoms of cervical cancer or abnormal Pap results include past medical history and physical examination, colposcopy, cervical biopsies, endocervical curettage (endocervical scraping), cone biopsy, loop electrosurgical procedure (LEEP, LLETZ), cold knife cone biopsy, and other imaging tests such as chest x-ray, computed tomography (CT), magnetic resonance imaging (MRI), intravenous urography, and positron emission tomography (PET scan).

Various external factors add to the expanding prevalence of cervical disease, around the world. These incorporate rising number of female smokers, huge number of patients experiencing HPV contamination, developing obese population (age group 21 to 60 years) and expanding occurrences of unsafe sex, especially among youngsters. Cancer awareness programs and early diagnosis likewise add to the development of this market. Technological developments in cervical cancer diagnostic test along with advanced laboratory testing procedures are boosting the demand majorly in Asia Pacific and Europe.

Inaccurate Pap smear testing, low grade vaccination, ineffectual medical services foundation and cancer institutes, less awareness about cervical malignancy, stringent government regulations and cheap & alternative approach towards cervical cancer diagnosis in developing nations are a few external factors, which hinder the development of worldwide cervical cancer diagnostic test market. New and advance technology assessment in laboratory testing, increasing population in developing nations such as India, China, Brazil and others and healthcare infrastructure improvements in rising economies are factors spur revenue growth in this market.

Other prominent drivers include low immunity factor in women working in developing countries due to deficiency of right nutritional intake, upsurge of human papillomavirus in females, higher usage of oral contraceptive pills by females and having multiple sex partners with unsafe sex.

"Pap Test Type Segment is expected to Register Higher Growth in the Developing Nations by the End of 2026"

In the past decade, various studies and research have shown that the regular history of corrective diagnostic testing have significantly affected the rate of cancer worldwide.

A Pap test is the most widely recognized test used to analyze for early changes in cells that can prompt cervical malignancy, also known as Pap smear. It includes gathering a sample of cells from the cervix. A portion of the cells gathered from the cervix during a Pap smear test may likewise be tried for human papillomavirus, additionally called HPV. Contamination with HPV is a hazard factor for cervical tumor. Pap smear tests give ongoing comprehension of current cell development, and show whether abnormal cell development is probably going to become more cancerous in the near term if left untreated.

According to American Cancer Society and World Health Organization, top quality screening with Pap and HPV testing has extraordinarily lessened mortality from cervical cancer. Since the presentation of Pap testing in the U.S. in the 1950s, cervical tumor, once the most regular reason for deaths due to malignancy in females, now positions fourteenth, which denotes a 70 percent decrease over that time range. This decrease in mortality is the immediate consequence of Pap and HPV diagnostics that have expanded detection of cervical cancer at the beginning of the diagnosis, lessening the general frequency of cervical cancer worldwide.

In April, 2014, the U.S. FDA approved the utilization of single HPV DNA test (Cobas test, by Roche) as a first-line principal screening test for use only for females age 25 years and older. This particular test identifies each of HPV types mainly 18 & 16 and gives collective marks for 12 supplementary risky HPV categories.

"Increasing Prevalence of Cervical Cancer Along With Advanced Diagnostic Procedures is Gaining Traction in Developing Economies"

North America spearheaded the market in 2017 owing to the presence of established players along with increasing incidences of cervical cancer in the U.S., as indicated by a report published by American Cancer Society, around 4000 females die due to cervical cancer. As per the research study, The American Cancer Society projections for cervical cancer in the U.S for 2018 are; around 13,000 fresh cases of cervical cancer will be diagnosed in females and around 4,100 females will die from this disease. However, deaths from cervical malignancy in the U.S keep on declining by around 2 percent a year. This decrease is basically due to the board utilization of the Pap test to identify cervical variations and permit early treatment.

Expanding number of techniques with cervical cancer diagnostic test alongside rising approvals from the U.S FDA is relied upon to drive development of the worldwide cervical cancer diagnostic test market. Rising trend of HPV test procedures alone in the U.S. and Europe along with increasing awareness for new computerized diagnostic tests and cervical cancer screening programs is gaining momentum in the global market.

Moreover, Asia Pacific is relied upon to indicate fast development in cervical cancer diagnostic test market, attributable to expanding R&D and approval of novel test kits and instruments in India and China. Additionally, increasing prevalence of cervical cancer, increase in acceptance of international brands in developing nations, technology assessment with rise in FDA approval for Pap and HPV testing and developing need for advance diagnostic procedures along with colposcopy, cystoscopy, cone biopsy and imaging tests and its awareness is expected to drive the market for cervical cancer diagnostic test during the forecast period.

"Dominance of Established Multinational Players with Strong Product Portfolio Makes Market Penetration Difficult For Emerging Players"

Major players in the cervical cancer diagnostic test market are Hologic Corporation, Becton, Dickinson and Company, Qiagen N.V., Siemens Healthcare, Guided Therapeutics Inc., Ascon Medical Instruments Pvt Ltd, Hoffmann-La Roche., Cooper Surgical Inc., Cardinal Health, Inc., Beckman Coulter Inc. and others. These manufacturers are implementing growth strategies along with new technology assessment along with approvals for new diagnostic kits and instruments for cancer, partnerships with medical technology companies to increase economic benefits. In 2014, Roche produced an automated CINtec PLUS cytology test to eliminate unhealthy tissue from the cervix site before the growth of cancerous cells. Furthermore, Roche also declared they received a U.S.FDA approval for Avastin, a combination of medicine plus chemotherapy for treating progressive cervical cancer patients.

Historical & Forecast Period

This study report represents analysis for each segment from 2016 to 2026 considering 2017 to be the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period from 2018 to 2026.

The current report also comprehends qualitative market assessment factors such as market trends, key market drivers, restraints and opportunities that gives a better market understanding of the overall cervical cancer diagnostic test market. Furthermore, the report also comprises graphical representation of competitive landscape based on their market initiatives and strategies, product portfolio and business strengths. Key industrial players profiled in the study report are Hologic Corporation, Becton, Dickinson and Company, Qiagen N.V., Siemens Healthcare, Guided Therapeutics Inc., Ascon Medical Instruments Pvt Ltd, Hoffmann-La Roche., Cooper Surgical Inc., Cardinal Health, Inc., Beckman Coulter Inc. and others.

Key questions answered in this report

• What are the current market trends and dynamics in the cervical cancer diagnostic test market and valuable opportunities for emerging players?
• Market positioning of major key players operating in the market?
• Which segment accounts for the fastest CAGR during the forecast period?
• Which end-user holds a larger market share and why?
• What is the impact of high cost of screening tests on the cervical cancer diagnostic test market?
• Are low and middle-income economies investing in the cervical cancer diagnostic test market?
• What is the market trend and dynamics in emerging markets such as Japan, Latin America and Middle East & Africa?